Skip to main content
MedinCell S.A. logo

MedinCell S.A. — Investor Relations & Filings

Ticker · MEDCL ISIN · FR0004065605 LEI · 969500R79U6PXCL2FF46 PA Manufacturing
Open in API
Filings indexed 520 across all filing types
Latest filing 2026-01-28 Earnings Release
Country FR France
Listing PA MEDCL

About MedinCell S.A.

https://www.medincell.com/en/

MedinCell S.A. is a pharmaceutical company at the commercial stage that specializes in the development of long-acting injectable (LAI) therapies. The company's core is its proprietary BEPO® technology platform, which enables the controlled and sustained release of active pharmaceutical ingredients over periods ranging from days to months after a single injection. This technology forms a fully biodegradable depot in situ, designed to improve treatment efficiency, enhance patient compliance, and increase the global accessibility of medicines. MedinCell develops a portfolio of LAI products across various therapeutic areas, including psychiatry, advancing its pipeline through both internal research and strategic partnerships with other pharmaceutical organizations.

Recent filings

Filing Released Lang Actions
Inside Information / Other news releases
Earnings Release Classification · 95% confidence The document is a press release from Medincell regarding the financial performance of its partner, Teva Pharmaceuticals, specifically concerning the product UZEDY and the upcoming regulatory submission for Olanzapine LAI. It provides key financial highlights (net sales, outlook) and strategic updates. While it mentions Teva's earnings, it is an initial announcement of these highlights rather than a full financial report or a transcript. Therefore, it fits the definition of an Earnings Release (ER). FY 2025
2026-01-28 English
Franchissement de seuil
Major Shareholding Notification Classification · 100% confidence The document is an official notice from the Autorité des marchés financiers (AMF) regarding a 'Déclaration de franchissement de seuil' (threshold crossing declaration). It explicitly states that Polar Capital LLP has crossed the 5% ownership threshold of Medincell. This falls directly under the definition of a Major Shareholding Notification.
2026-01-27 French
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a standard regulatory disclosure required by Article 223-16 of the AMF General Regulation, which mandates that listed companies periodically report the total number of shares and voting rights. This type of filing is a routine regulatory requirement regarding capital structure and does not fit into specific categories like M&A, earnings, or dividends. Therefore, it is classified as a Regulatory Filing (RNS).
2026-01-21 French
Inside Information / Other news releases
Transaction in Own Shares Classification · 100% confidence The document is a press release from Medincell detailing the status of its liquidity contract with Rothschild Martin Maurel for the period of July 1, 2025, to December 31, 2025. It provides a summary of share transactions (buy/sell side) and the resources held in the liquidity account. This type of disclosure is a standard regulatory requirement for companies listed on European exchanges (like Euronext) to report on share repurchase/liquidity programs. Since it reports on the company's own share transactions conducted under a liquidity contract, it falls under the 'Transaction in Own Shares' category.
2026-01-20 English
Informations privilégiées / Autres communiqués
Transaction in Own Shares Classification · 100% confidence The document is a 'Bilan semestriel du contrat de liquidité' (Semi-annual liquidity contract report) for Medincell. It details the transactions (purchases and sales) conducted by the liquidity provider (Rothschild Martin Maurel) on behalf of the company over a specific six-month period (July 1, 2025, to December 31, 2025). This type of disclosure is a standard regulatory requirement for companies listed on Euronext to report on their share buyback/liquidity programs. Since it reports on the company's own share transactions, it falls under the 'Transaction in Own Shares' category.
2026-01-20 French
Informations privilégiées / Autres communiqués
Report Publication Announcement Classification · 100% confidence The document is a press release from Medincell announcing its 'calendrier financier 2026' (financial calendar for 2026). It lists upcoming dates for annual results, the Annual General Meeting, and interim results. This type of announcement, which provides the schedule for future report publications, falls under the 'Report Publication Announcement' (RPA) category.
2026-01-12 French

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.